Systemic reaction to omalizumab.

نویسنده

  • Bradley Chipps
چکیده

1. Kim JS, Sinacore JM, Pongracic JA. Parental use of Epipen for children with food allergies. J Allergy Clin Immunol. 2005;116: 164–168. 2. Sicherer SH, Forman JA, Noone SA. Use assessment of selfadministered epinephrine among food-allergic children and pediatricians. Pediatrics. 2000;105:359–362. 3. Meglio P, Bartone E, Plantamura M, Arabito E, Giampietro PG. A protocol for oral desensitization in children with IgEmediated cow’s milk allergy. Allergy. 2004;59:980–987. 4. Patriarca G, Nucera E, Roncallo C, et al. Oral desensitizing treatment in food allergy clinical and immunological results. Aliment Pharmacol Ther. 2003;17:459–465. 5. Nucera E, Schiavino D, D’Ambrosio C, et al. Immunological aspects of oral desensitization in food allergy. Dig Dis Sci. 2000;45:637–641. 6. Patriarca G, Schiavino D, Nucera E, et al. Food allergy in children: results of a standardized protocol for oral desensitization. Hepatogastroenterology. 1998;5(19):52–58. 7. Wuthrich B. Oral desensitization with cow’s milk in cow’s milk allergy. Pro! Monogr Allergy. 1996;32:236–240. 8. Patriarca C, Romano A, Venuti A, et al. Oral specific hyposensitization in the management of patients allergic to food. Allergol Unopathol (Madr).1984;12:275–281. 9. Mastrandrea F. The potential role of allergen-specific sublingual immunotherapy in atopic dermatitis. Am J Clin Dermatol. 2004;5:281–294.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Unpredicted adverse reaction to omalizumab.

Despite promising reports of the use of omalizumab as add-on therapy in patients with systemic mastocytosis and recurrent anaphylaxis during specific venom immunotherapy (VIT), unpredicted adverse effects may lead to therapy failure. We present the case of a patient with systemic mastocytosis and Hymenoptera venom allergy who was administered omalizumab as add-on therapy to improve VIT tolerabi...

متن کامل

Omalizumab treatment of systemic mast cell activation disease: experiences from four cases.

We report on the outcome of 4 patients with therapy-resistant systemic mast cell activation disease (MCAD) treated with the anti-IgE monoclonal antibody omalizumab in compassionate use. Two patients achieved an impressive persistent clinical response to treatment with omalizumab. In the third patient symptoms gradually improved. In the fourth patient omalizumab treatment had to be discontinued ...

متن کامل

Cutaneous and Gastrointestinal Symptoms in Two Patients with Systemic Mastocytosis Successfully Treated with Omalizumab

The pathogenesis of mastocytosis is not well defined and thus treatment remains challenging and remains on a palliative basis. We present two cases (a 48-year-old woman and a 57-year-old man) with indolent systemic mastocytosis in whom omalizumab (anti-IgE) reduced gastrointestinal and cutaneous symptoms significantly. This observation provides additional insight into the effects of omalizumab ...

متن کامل

Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab.

Immunotherapy is an established mode of treatment for Hymenoptera venom anaphylaxis, although adverse reactions may occur. We report the case of a 33-year-old woman, the wife of a beekeeper, who experienced a systemic allergic reaction following a bee sting. Initial specific immunotherapy had to be stopped due to anaphylaxis (multiple immediate cardiovascular reactions). We looked for an altern...

متن کامل

Pretreatment by omalizumab allows allergen-specific immunotherapy in children and young adult with severe allergic asthma

Background Subcutaneous allergen-specific immunotherapy (SCIT) is a valuable treatment option for patients with controlled mild to moderate allergic asthma However, SCIT is contraindicated for patients with severe persistent asthma due to a potential systemic allergic reaction. Several studies in adolescents and adults with persistent allergic rhinitis and moderate persistent allergic asthma ha...

متن کامل

PD11 - Omalizumab in children: experience in the Immunoallergology Department

Results Ten pts were proposed to omalizumab: 8M, 2F with a mean age of 12.9 years ±3.9 [7-17]. All had bronchial asthma: 3severe allergic asthma, 5severe atopic eczema (AE), 1severe ocular allergy (OA) with risk for injury to the cornea by conjunctival edema and 1 cow’s milk protein allergy (CMA) with anaphylaxis during the protocol for oral tolerance induction (OTI). The mean duration of thera...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology

دوره 97 2  شماره 

صفحات  -

تاریخ انتشار 2006